The risk for CVD in COPD increased approximately 1.5-fold during the first 30 days after starting therapy with long-acting β2 agonists compared with ongoing or more prolonged use, lead author, Meng-Ting Wang, PhD, and coauthors write in JAMA Internal Medicine.

Doctors should be very vigilant with regard to any cardiovascular symptoms within 30 days of initiating LABA or LAMA treatment for COPD.